Biohaven Ltd. (NYSE: BHVN) (Biohaven) on Saturday presented preclinical data for BHV-1420 in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado. BHV-1420 is a novel TRAP extracellular protein degrader designed to selectively eliminate the anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies that drive membranous nephropathy (MN).
Biohaven stock catapulted more than 30% early Thursday after the FDA said it would review the company's embattled drug.
The transaction grants Ono exclusive rights for candidates BHV-1300, BHV-1310, and BHV-1320 across Taiwan, South Korea, and Japan.
Biohaven signs a $100 million Asian licensing agreement with Ono Pharmaceutical for its Phase 3 MoDE pan IgG degrader portfolio.
Biohaven (BHVN) signs a deal with Ono Pharma (OPHLF) to outlicense its MoDE pan IgG degrader portfolio in several Asian countries. Read more here.
Roche announced it's building autonomous AI-powered labs; how a clinical hold on an epilepsy trial could impact Biohaven
Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.
Biohaven has seen its share price fall over several time frames, yet the stock still carries a valuation that ultimately has to rest on what its balance sheet is worth. With the stock changing hands around US$13.19, the live question is how that market value lines up against the company’s book value relative to the broader pharmaceuticals and biotech industry. Over the past 3 years, Biohaven shareholders have seen the stock decline about 49.3%, which puts the focus squarely on whether its...
Biohaven's (BHVN) stock performance is likely to remain focused on the outlook for its Kv7 program a
Pivotal study enrolment has been paused while Biohaven characterises a metabolite of opakalim and its safety in humans.
Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment.
This is the newest page. Registered accounts read further back.